S-1/A: Synergy CHC Corp. Eyes Nasdaq Listing with $11.5 Million Common Stock Offering

Synergy CHC Corp. is seeking to list on the Nasdaq Global Market through an offering of 1,000,000 shares of common stock, with an estimated price range of $9.00 to $11.00 per share.

Summary

• Synergy CHC Corp. has filed an amendment to its S-1 registration statement for a proposed offering of 1,000,000 shares of common stock.
• The company estimates the initial public offering price to be between $9.00 and $11.00 per share.
• Synergy CHC Corp. has applied to list its common stock on the Nasdaq Global Market under the symbol SNYR.
• The offering includes a 30-day option for the underwriters to purchase up to 150,000 additional shares to cover over-allotments.
• Upon completion of the offering, officers and directors will hold approximately 54% of the voting power.
• The company intends to use the net proceeds to repay a portion of outstanding amounts under certain related party promissory notes and for general corporate purposes.
• Roth Capital Partners is acting as the sole book-running manager for the offering.
• Certain officers, directors, and stockholders have indicated an interest in participating in the offering, potentially purchasing approximately 270,000 shares.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, outlining the terms of the proposed stock offering. While it acknowledges risks, it also highlights the company's growth strategy and competitive strengths. The sentiment is neutral to slightly positive.

Positives

• The company intends to use the net proceeds to repay a portion of outstanding amounts under certain related party promissory notes and for general corporate purposes.

Negatives

• The company's common stock was shifted to the OTC Expert Market on September 28, 2021, which means that there are no longer publicly-available quotations of our common stock.
• There is no assurance that the company's application to list on Nasdaq will be approved.
• The company's officers and directors will hold a majority of the voting power of the capital stock through ownership of approximately 54% of the outstanding common stock.

Risks

• The document states that investing in the company's common stock involves a high degree of risk.
• If shares of the company's common stock are not approved for listing on Nasdaq, the offering will not be consummated.

Future Outlook

The company intends to use the net proceeds of this offering to repay a portion of outstanding amounts under certain related party promissory notes and for general corporate purposes.

Industry Context

The document mentions that the U.S. nutritional supplements retail industry is large and highly fragmented with few barriers to entry.

Related Party Transactions

• The company intends to use the net proceeds of this offering to repay a portion of outstanding amounts under certain related party promissory notes.
• Jack Ross, the company's Chief Executive Officer, is the owner of Kenek Brands Inc. and its sole officer and director.
• An affiliate of Knight is also the beneficial owner of approximately 19.6% of the company's outstanding common stock.
• The lender under the company's Amended and Restated Loan Agreement is Knight Therapeutics (Barbados) Inc.

Stakeholder Impact

• Existing shareholders may experience dilution.
• New investors will have an opportunity to invest in the company.
• The company's ability to execute its growth strategy may be enhanced by the capital raised.

Next Steps

• The company seeks approval for listing on the Nasdaq Global Market.
• The underwriters will market and sell the shares to the public.
• The company will use the net proceeds for the stated purposes.

Key Dates

Keywords

common stock, offering, Nasdaq, Synergy CHC Corp, IPO, underwriters, shares